PhageTech, Inc. is a Southern California company founded in 2014. PhageTech’s core technology was developed by two world-class researchers at the University of California, Irvine supported by a team of research scientists, postdoctoral researchers and graduate students. The collaboration between Dr. Reginald Penner and Dr. Gregory Weiss brought together two experts in analytical chemistry and molecular recognition.
The core bioconducting technology has been developed over ten years of intensive NIH-funded research, made possible through $2.2 MM in grants awarded to Dr. Penner and Dr. Weiss. PhageTech, Inc. has licensed proprietary diagnostic technology from the University of California, Irvine with the intent to develop and commercialize a new low-cost diagnostic platform utilizing disease-specific "bacteriophage" sensors that will enable rapid and sensitive detection of diseases at their earliest stages.
"PhageTech aims to deliver breakthrough diagnostic testing to physicians and patients"
Our Company's vision is to use bacteriophage (viruses that infect bacteria) engineered to recognize disease markers to supplant antibodies in immunoassays to deliver robust, inexpensive and rapid POC biosensors. PhageTech, Inc. aims to develop and commercialize affordable, simple to use, accurate sensors for the detection of deadly diseases which will save lives and lower healthcare costs worldwide.